Αρχική World News Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among... World News Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC Από Ogkologos - 7 Ιουλίου, 2025 879 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... 5 Δεκεμβρίου, 2024 LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by... 1 Μαΐου, 2024 The Caregiver Curve 15 Μαρτίου, 2021 Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... 10 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... Breast Cancer Patient Given 2 Years to Live is Now a... CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns